David A. Tess

2.3k total citations
45 papers, 1.1k citations indexed

About

David A. Tess is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, David A. Tess has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 24 papers in Pharmacology and 13 papers in Molecular Biology. Recurrent topics in David A. Tess's work include Drug Transport and Resistance Mechanisms (23 papers), Pharmacogenetics and Drug Metabolism (22 papers) and Computational Drug Discovery Methods (10 papers). David A. Tess is often cited by papers focused on Drug Transport and Resistance Mechanisms (23 papers), Pharmacogenetics and Drug Metabolism (22 papers) and Computational Drug Discovery Methods (10 papers). David A. Tess collaborates with scholars based in United States, Australia and India. David A. Tess's co-authors include Tristan S. Maurer, Dennis O. Scott, Manthena V. S. Varma, Li Di, Sangwoo Ryu, Sumathy Mathialagan, John Litchfield, Jian Lin, Bo Feng and Michael C. Linhares and has published in prestigious journals such as Nature Communications, Journal of Medicinal Chemistry and European Heart Journal.

In The Last Decade

David A. Tess

44 papers receiving 1.0k citations

Peers

Countries citing papers authored by David A. Tess

Since Specialization

Citations

This map shows the geographic impact of David A. Tess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Tess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Tess more than expected).

Fields of papers citing papers by David A. Tess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Tess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Tess. The network helps show where David A. Tess may publish in the future.

Co-authorship network of co-authors of David A. Tess

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Tess. A scholar is included among the top collaborators of David A. Tess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Tess. David A. Tess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors 2024 ·Clinical Pharmacokinetics ·Rui Li, Emi Kimoto, (unknown), David A. Tess, Manthena V. S. Varma	2
2	Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model 2024 ·Nature Communications ·Brian D. Adair, Conroy O. Field, José Luís Izquierdo Alonso, Jian-Ping Xiong, Shi‐Xian Deng, (unknown), (unknown), Clary B. Clish, (unknown), Mark Yeager, Youzhong Guo, David A. Tess, Donald W. Landry, Mortimer Poncz, M. Amin Arnaout	5
3	Prediction of Drug-Drug Interactions for Highly Plasma Protein Bound Compounds 2024 ·The AAPS Journal ·David A. Tess, (unknown), Jian Lin, Rui Li, Li Di	1
4	A Novel Milli-fluidic Liver Tissue Chip with Continuous Recirculation for Predictive Pharmacokinetics Applications 2023 ·The AAPS Journal ·Shiny Amala Priya Rajan, Jason Sherfey, (unknown), Lauren M. Nichols, Jeff Smith, (unknown), Eugene P. Kadar, (unknown), (unknown), (unknown), David A. Tess, J Gosset, Jennifer L. Liras, Emily Geishecker, R. Scott Obach, Murat Cirit	17
5	In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance of Human and Preclinical Species with Liver Microsomes and Hepatocytes 2023 ·The AAPS Journal ·David A. Tess, George Chang, Christopher Keefer, Anthony Carlo, Rhys Jones, Li Di	26
6	Study of the ketohexokinase inhibitor PF‐06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy 2023 ·Clinical and Translational Science ·Ruolun Qiu, Kari R. Fonseca, Arthur Bergman, Jian Lin, David A. Tess, Lauren A. Newman, (unknown), Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues	1
7	Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease 2022 ·Drug Metabolism and Disposition ·Yan Weng, Kari R. Fonseca, Yi‐An Bi, Sumathy Mathialagan, Keith Riccardi, Elaine Tseng, (unknown), (unknown), David A. Tess, A. David Rodrigues, Amit S. Kalgutkar, John Litchfield, Li Di, Manthena V. S. Varma	6
8	In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species 2022 ·Pharmaceutical Research ·David A. Tess, Sangwoo Ryu, Li Di	17
9	Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes 2021 ·Drug Metabolism and Disposition ·Elaine Tseng, Heather Eng, Jian Lin, Matthew A. Cerny, David A. Tess, Theunis C. Goosen, R. Scott Obach	27
10	Organic Anion–Transporting Polypeptide 1B1/1B3–Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro–In Vivo Evaluation in Cynomolgus Monkey 2021 ·Journal of Pharmacology and Experimental Therapeutics ·Heather Eng, Yi‐An Bi, Mark A. West, Sangwoo Ryu, Emi Yamaguchi, Rachel E. Kosa, David A. Tess, David A. Griffith, John Litchfield, Amit S. Kalgutkar, Manthena V. S. Varma	15
11	Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs 2020 ·Journal of Medicinal Chemistry ·David A. Tess, Heather Eng, Amit S. Kalgutkar, John Litchfield, David J. Edmonds, David A. Griffith, Manthena V. S. Varma	15
12	Comparison of Fraction Unbound Between Liver Homogenate and Hepatocytes at 4°C 2020 ·The AAPS Journal ·Keith Riccardi, Sangwoo Ryu, David A. Tess, Rui Li, Lina Luo, Nathaniel Johnson, (unknown), (unknown), Li Di	10
13	Structural attributes influencing unbound tissue distribution 2019 ·European Journal of Medicinal Chemistry ·Christine C. Orozco, Karen Atkinson, Sangwoo Ryu, George Chang, Christopher Keefer, Jian Lin, Keith Riccardi, (unknown), David A. Tess, Kevin J. Filipski, Amit S. Kalgutkar, John Litchfield, Dennis O. Scott, Li Di	21
14	A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Medated Mechanisms Using Suspended Human Hepatocytes 2019 ·Drug Metabolism and Disposition ·Keith Riccardi, David A. Tess, Jian Lin, (unknown), Sangwoo Ryu, Karen Atkinson, Li Di, Rui Li	32
15	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: “SLC-Phenotyping” Using Primary Human Hepatocytes 2019 ·Journal of Pharmacology and Experimental Therapeutics ·Yi‐An Bi, Chester Costales, Sumathy Mathialagan, Mark A. West, (unknown), Sarah Lazzaro, Laurie Tylaska, Renato J. Scialis, Hui Zhang, John P. Umland, Emi Kimoto, David A. Tess, Bo Feng, Larry M. Tremaine, Manthena V. S. Varma, A. David Rodrigues	66
16	Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines 2018 ·Drug Metabolism and Disposition ·Keith Riccardi, Sangwoo Ryu, Jian Lin, Phillip D. Yates, David A. Tess, Rui Li, (unknown), (unknown), (unknown), George Chang, Li Di	34
17	Organic Anion Transporter 2–Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability–Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs 2018 ·Journal of Pharmacology and Experimental Therapeutics ·Emi Kimoto, Sumathy Mathialagan, Laurie Tylaska, Mark Niosi, Jian Lin, Anthony Carlo, David A. Tess, Manthena V. S. Varma	46
18	Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging 2015 ·Molecular Imaging and Biology ·Nilantha Bandara, Alex Zheleznyak, (unknown), David A. Griffith, Chris Limberakis, David A. Tess, Jianqing Chen, Rikki N. Waterhouse, Suzanne E. Lapi	13
19	Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide 2011 ·Bioorganic & Medicinal Chemistry Letters ·Ralph P. Robinson, Jeremy A. Bartlett, Peter Bertinato, (unknown), (unknown), Patrick M. Foley, (unknown), Martha L. Minich, (unknown), Matthew R. Reese, (unknown), Andrew G. Swick, David A. Tess, Alfin D. N. Vaz, Angela Wolford	10
20	Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jennifer Lafontaine, (unknown), (unknown), John R. Hadcock, Diane M. Hargrove, Michael C. Linhares, Kelly A. Martin, Tristan S. Maurer, Nancy A. Nardone, David A. Tess, Paul DaSilva‐Jardine	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact